Skip to main content
Journal cover image

The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis.

Publication ,  Journal Article
Wright, KA; Perfect, JR; Ritter, W
Published in: J Antimicrob Chemother
September 1990

We studied the pharmacokinetics and efficacy of BAY R3783, a new antifungal azole compound, in rabbits and compared it with fluconazole and itraconazole. BAY R3783 has at least two active metabolites, BAY U3624 and BAY U3625. We measured serum concentrations of all three compounds; the peak serum level for the parent compound was approximately two hours post dose. BAY R3783 and its metabolites also crossed the blood-CSF barrier; the mean CSF level of BAY R3783 was 30.5% of simultaneous serum levels. The in-vivo activity of the azoles was compared in a model of cryptococcal meningitis in immunosuppressed rabbits. BAY R3783, fluconazole and itraconazole all reduced yeast counts in the CSF with equal efficacy over ten days of therapy at 100 mg/day. In this model, BAY R3783 was effective in the treatment of cryptococcal meningitis.

Duke Scholars

Published In

J Antimicrob Chemother

DOI

ISSN

0305-7453

Publication Date

September 1990

Volume

26

Issue

3

Start / End Page

387 / 397

Location

England

Related Subject Headings

  • Triazoles
  • Rabbits
  • Microbiology
  • Meningitis
  • Ketoconazole
  • Itraconazole
  • Fluconazole
  • Cryptococcus neoformans
  • Cryptococcosis
  • Animals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Wright, K. A., Perfect, J. R., & Ritter, W. (1990). The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J Antimicrob Chemother, 26(3), 387–397. https://doi.org/10.1093/jac/26.3.387
Wright, K. A., J. R. Perfect, and W. Ritter. “The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis.J Antimicrob Chemother 26, no. 3 (September 1990): 387–97. https://doi.org/10.1093/jac/26.3.387.
Wright KA, Perfect JR, Ritter W. The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J Antimicrob Chemother. 1990 Sep;26(3):387–97.
Wright, K. A., et al. “The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis.J Antimicrob Chemother, vol. 26, no. 3, Sept. 1990, pp. 387–97. Pubmed, doi:10.1093/jac/26.3.387.
Wright KA, Perfect JR, Ritter W. The pharmacokinetics of BAY R3783 and its efficacy in the treatment of experimental cryptococcal meningitis. J Antimicrob Chemother. 1990 Sep;26(3):387–397.
Journal cover image

Published In

J Antimicrob Chemother

DOI

ISSN

0305-7453

Publication Date

September 1990

Volume

26

Issue

3

Start / End Page

387 / 397

Location

England

Related Subject Headings

  • Triazoles
  • Rabbits
  • Microbiology
  • Meningitis
  • Ketoconazole
  • Itraconazole
  • Fluconazole
  • Cryptococcus neoformans
  • Cryptococcosis
  • Animals